Company intelligence / Profile preview

MerLion Pharmaceuticals

Berlin, Berlin, Germanymerlionpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Finafloxacin has been approved by FDA and Health Canada for acute otitis externa (Xtoro™). It has completed Phase II trials for complicated urinary tract infections (cUTIs) including pyelonephritis. The company is also developing finafloxacin for systemic application against Burkholderia pseudomallei infections (Melioidosis).

Therapeutic areas: Infectious DiseasesNephrology
Modalities: Small moleculesAntibioticsFluoroquinolones
Industry: Biotech

Drug pipeline

2 assets

finafloxacin

Approved

1 more asset in the full pipeline.

Request access →

Partnerships

UK Defence Science and Technology Laboratory (Dstl)US Defense Threat Reduction Agency (DTRA)

Beyond the preview

Go deeper on MerLion Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MerLion Pharmaceuticals.

Explore the full profile